Mature HIV-like particles produced from single Semliki Forest Virus-derived expression vector

Journal of Microbiology and Biotechnology

Volumn 15, Issue 6, 2005, Pages 1229-1239

  Kim, Eun ^a   Poo, Haryoung ^b   Sung, Moon Hee ^c   Kim, Chul Joong ^a  

^a Chungnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Kookmin University   (South Korea)

Author keywords

HIV 1; Semliki Forest Virus vector; Vaccine; Virus like praticle

Indexed keywords

ENVELOPE PROTEIN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE SEQUENCE; HAMSTER; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGOLD ELECTRON MICROSCOPY; KIDNEY CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTICLE SIZE; PROTEIN ANALYSIS; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEMLIKI FOREST ALPHAVIRUS; SEQUENCE ANALYSIS; STRUCTURAL GENE; SUCROSE GRADIENT; VIRUS PARTICLE; WESTERN BLOTTING;

ANIMALIA; CRICETINAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RABBIT FIBROMA VIRUS; SEMLIKI FOREST VIRUS;

EID: 33646744699     PISSN: 10177825     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Abel, K., L. Compton, T. Rourke, D. Montefiori, D. Lu, K. Rothaeusler, L. Fritts, K. Bost, and C. J. Miller. 2003. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J. Virol. 77: 3099-3118.
2. Adamson, C. S., A. Davies, Y. Soneoka, M. Nermut, K. Mitrophanous, and I. M. Jones. 2003. A block in virus-like particle maturation following assembly of murine leukaemia virus in insect cells. Virology 314: 488-496.
3. Berglund, P., M. Quesada-Rolander, P. Putkonen, G. Biberfeld, R. Thorstensson, and P. Liljestrom. 1997. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retroviruses 13: 1487-1495.
4. Campbell, S. and A. Rein. 1999. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J. Virol. 73: 2270-2299.
5. Choi, E. A., E. Kim, Y. I. Oh, K. S. Shin, H. S. Kim, and C. J. Kim. 2002. Expression of rotavirus capsid proteins VP6 and VP7 in mammalian cells using Semliki Forest virus-based expression system. J. Microbiol. Biotechnol. 12: 463-469.
6. Deml, L., G. Kratochwil, N. Osterrieder, R. Knuchel, H. Wolf, and R. Wagner. 1997. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 235: 10-25.
7. Deml, L., R. Schirmbeck, J. Reimann, H. Wolf, and R. Wagner. 1997. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 235: 26-39.
8. Fleeton, M. N., P. Liljestrom, B. J. Sheahan, and G. J. Atkins. 2000. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J. Gen. Virol. 81: 749-758.
9. Gao, F., Y. Li, J. M. Decker, F. W. Peyerl, F. Bibollet-Ruche, C. M. Rodenburg, Y. Chen, D. R. Shaw, S. Allen, R. Musonda, G. M. Shaw, A. J. Zajac, N. Letvin, and B. H. Hahn. 2003. Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: In vitro expression and immune responses in DNA-vaccinated mice. AIDS Res. Hum. Retroviruses 19: 817-823.
10. Golding, B., N. Eller, L. Levy, P. Beining, J. Inman, N. Matthews, D. E. Scott, and H. Golding. 2002. Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus. Vaccine 20: 1445-1450.
11. Gonzalo, R. M., D. Rodriguez, A. Garcia-Sastre, J. R. Rodriguez, P. Palese, and M. Esteban. 1999. CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17: 887-892.
12. Gzyl, J., E. Bolesta, A. Wierzbicki, D. Kmieciak, T. Naito, M. Honda, K. Komuro, Y. Kaneko, and D. Kozbor. 2004. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses. Virology 318: 493-506.
13. Hamajima, K., Y. Hoshino, K. Q. Xin, F. Hayashi, K. Tadokoro, and K. Okuda. 2002. Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine. Clin. Immunol. 102: 12-18.
14. Hanke, T., C. Barnfield, E. G. Wee, L. Agren, R. V. Samuel, N. Larke, and P. Liljestrom. 2003. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J. Gen. Virol. 84: 361-368.
15. Heeney, J. L., G. Koopman, B. Rosenwirth, W. Bogers, J. van Dijk, I. Nieuwenhuis, H. Niphuis, P. ten Haaft, T. Hanke, G. Rhodes, P. Berglund, A. Burny, F. Bex, G. Sutter, and P. Liljestrom. 2000. A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens. J. Med. Primatol. 29: 268-273.
16. Hewer, R. and D. Meyer. 2003. Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits. Mol. Immunol. 40: 327-335.
17. Hofmann-Lehmann, R., J. Vlasak, A. L. Williams, A. L. Chenine, H. M. McClure, D. C. Anderson, S. O'Neil, and R. M. Ruprecht. 2003. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17: 157-166.
18. Iida, T., T. Kuwata, M. Ui, H. Suzuki, T. Miura, K. Ibuki, H. Takahashi, T. Yamamoto, J. Imanishi, M. Hayami, and M. Kita. 2004. Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma. Arch. Virol. 149: 743-757.
19. Jacks, T., M. D. Power, F. R. Masiarz, P. A. Luciw, P. J. Barr, and H. E. Varmus. 1988. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331: 280-283.
20. Kallinteris, N. L., X. Lu, S. Wu, H. Hu, Y. Li, J. V. Gulfo, R. E. Humphreys, and M. Xu. 2003. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 21: 4128-4132.
21. Kim, B. G., H. S. Jeong, S. Y. Baek, J. H. Shin, J. O. Kim, K. I. Min, S. R. Ryu, B. S. Min, D. K. Kim, Y. S. Jeong, and S. N. Park. 2005. Validation of one-step real-time RT-PCR assay in combination with automated RNA extraction for rapid detection and quantitation of Hepatitis C virus RNA for routine testing in clinical specimens. J. Microbiol. Biotechnol. 15: 595-602.
22. Kim, H., S. J. Kim, S. N. Park, and J. W. Oh. 2004. Antiviral effect of Amphotericin B on Japanese Encephalitis virus replication. J. Microbiol. Biotechnol. 14: 121-127.
23. Kong, W. P., Y. Huang, Z. Y. Yang, B. K. Chakrabarti, Z. Moodie, and G. J. Nabel. 2003. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77: 12764-12772.
24. Li, K. J. and H. Garoff. 1996. Production of infectious recombinant Moloney murine leukemia virus particles in BHK cells using Semliki Forest virus-derived RNA expression vectors. Proc. Natl. Acad. Sci. USA 93: 11658-11663.
25. Liljestrom, P. and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N.Y.) 9: 1356-1361.
26. Lorin, C., L. Mollet, F. Delebecque, C. Combredet, B. Hurtrel, P. Charneau, M. Brahic, and F. Tangy. 2004. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78: 146-157.
27. Luo, L., Y. Li, and C. Y. Kang. 2003. Budding and secretion of HIV Gag-Env virus-like particles from recombinant human adenovirus infected cells. Virus Res. 92: 75-82
28. Mata, M., P. J. Travers, Q. Liu, F. R. Frankel, and Y. Paterson. 1998. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J. Immunol. 161: 2985-2993.
29. McGettigan, J. P., K. Naper, J. Orenstein, M. Koser, P. M. McKenna, and M. J. Schnell. 2003. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J. Virol. 77: 10889-10899.
30. Mossman, S. P., F. Bex, P. Berglund, J. Arthos, S. P. O'Neil, D. Riley, D. H. Maul, C. Bruck, P. Momin, A. Burny, P. N. Fultz, J. I. Mullins, P. Liljestrom, and E. A. Hoover. 1996. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J. Virol. 70: 1953-1960.
31. Muriaux, D., J. Mirro, D. Harvin, and A. Rein. 2001. RNA is a structural element in retrovirus particles. Proc. Natl. Acad. Sci. USA 98: 5246-5251.
32. Mwau, M., I. Cebere, J. Sutton, P. Chikoti, N. Winstone, E. G. Wee, T. Beattie, Y. H. Chen, L. Dorrell, H. McShane, C. Schmidt, M. Brooks, S. Patel, J. Roberts, C. Conlon, S. L. Rowland-Jones, J. J. Bwayo, A. J. McMichael, and T. Hanke. 2004. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85: 911-919.
33. Nilsson, C., B. Makitalo, P. Berglund, F. Bex, P. Liljestrom, G. Sutter, V. Erfle, P. ten Haaft, J. Heeney, G. Biberfeld, and R. Thorstensson. 2001. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19: 3526-3536.
34. Ohagen, A., R. B. Luftig, A. S. Reicin, L. Yin, K. Ikuta, T. Kimura, S. P. Goff, and S. Hoglund. 1997. The morphology of the immature HIV-1 virion. Virology 228: 112-114.
35. Perri, S., C. E. Greer, K. Thudium, B. Doe, H. Legg, H. Liu, R. E. Romero, Z. Tang, Q. Bin, T. W. Jr. Dubensky, M. Vajdy, G. R. Otten, and J. M. Polo. 2003. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77: 10394-10403.
36. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
37. Vignuzzi, M., S. Gerbaud, S. van der Werf, and N. Escriou. 2001. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J. Gen. Virol. 82: 1737-1747.
38. Wagner, R., L. Deml, R. Schirmbeck, M. Niedrig, J. Reimann, and H. Wolf. 1996. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology 220: 128-140.
39. Yao, Q., F. M. Kuhlmann, R. Eller, R. W. Compans, and C. Chen. 2000. Production and characterization of simian-human immunodeficiency virus-like particles. AIDS Res. Hum. Retroviruses 16: 227-236.
40. Yao, Q., V. Vuong, M. Li, and R. W. Compans. 2002. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 20: 2537-2545.